Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?
Clinical trial NCT06922656 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06922656
- Sponsor
- Dasman Diabetes Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-15
- Primary completion
- 2026-09-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.